The efficacy of ginseng supplement in the prevention of cardiac toxicity induced by anthracyclines

Evaluating the efficacy of ginseng supplement in the prevention of cardiac toxicity induced by anthracyclines in breast cancer patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141227020441N7

Enrollment

Registered

2020-01-19

Start date

2019-04-04

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiac disease. Cardiomyopathy due to drug and external agent

Interventions

Intervention 1: Intervention group: The standard chemotherapy regimen beside 1g ginseng daily for 3 monthes. Intervention 2: Control group: The standard chemotherapy regimen beside 1g capsules contain

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The ages of 18 to 65 years Patients with non-metastatic breast cancer Receiving the first course of anthracycline based chemotherapy

Exclusion criteria

Exclusion criteria: History of therapy with anthracyclines Metastatic or recurrent breast cancer History of solid tumors and receiving systemic therapy LVEF below 50% History of chronic diseases ( DM, cardiac disease. renal failure) Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Cardiotoxicity will be assessed based on LVEF and Trop I. Timepoint: will be evaluated baseline and after completion of chemotherapy cycles (3 monthes). Method of measurement: LVEF and Trop I will be assessed with echocardiography and blood samples respectively.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Foroughinia

Shiraz University of Medical Sciences

foroughinia@sums.ac.ir+98 7132424128233

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026